D4Uâ„¢
Therapeutic Segment:
Supplement
Generic Name:
Cholecalciferol (Vitamin D3)
Description:
Cholecalciferol is the naturally occurring form of Vitamin D, also called Vitamin D3. It is produced from 7- dehydrocholesterol, a sterol present in mammalian skin, by ultraviolet irradiation. Calciferol is involved in bone fixation of calcium. It is indicated in prevention and treatment of Vitamin D deficiencies.
Indication:
Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins; as such it may impair intestinal absorption of any of Vitmain-D. Thiazides: Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. Some reports have shown that the concomitant administration of thiazides with Vitamin-D causes hypercalcemia, Therefore, precautions should be taken when co-administration is necessary. Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias. Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of Vitamin D, Reductions in serum endogenous Vitamin D concentration have been observed following the administration of 300mg/day to 1200mg/day ketoconazole for a week to healthy men. Corticosteroids: A relationship of functional antagonism exists between Vitamin D analogues, which promote calcium absorption and corticosteroids, which inhibit calcium absorption. Phosphate-Binding Agents: Since Vitamin D also has effect on phosphate transport in the intestine, kidneys and bones, the dosage of phosphate binding agents must be adjusted in accordance with the serum phosphate concentration. Vitamin D: The co-administration of any of the Vitamin D analogues should be avoided as this could create possible additive effects and hypercalcemia. Calcium Supplements: Uncontrolled intake of additional calcium-containing preparations should be avoided. Magnesium: Magnesium-containing preparations (e.g., antacids) may cause hypermagnesemia and should therefore not be taken during therapy with Vitamin D by patients on chronic renal dialysis.
Formulation:
Oral Drop
Pack Size:
- 5mg/ml
